Table 1 The clinical manifestations of patients with anti-SRP antibodies and another MSA
From: What should we expect when two myositis-specific antibodies coexist in a patient
Age/gender | Muscle weakness | Skin lesion | Raynaud’s phenomenon | Arthritis | Mechanics hands | Tumor | ILD | CK | MSAs | Muscle biopsy | Therapy | Outcome | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient 1 | 33/F | + | − | − | + | − | − | − | Normal | SRP, TIF1-γ | Mild | GC | Recover |
Patient 2 | 78/F | − | − | − | + | − | − | + | Normal | SRP, Jo1 | NA | GC + CTX | Partial remission |
Patient 3 | 74/M | + | − | − | − | − | − | + | 3750 | SRP, EJ | NAM | GC + IVIG | Death |
REF4 [5] | 70/F | + | + | + | − | NA | − | + | 1100 | SRP, Jo1 | PM | GC + CTX | Mild improvement |
REF5 [6] | 37/F | + | − | + | − | − | − | + | 21,808 | SRP, PL12 | NAM | GC + IVIG + CTX | Partial remission |
REF6 [7] | 61/M | + | + | − | − | − | Gastric cancer | + | 5685 | SRP, Jo1 | DM | Gastrectomy, GC | Death |
REF7 [8] | 33/F | NA | NA | NA | + | NA | NA | + | NA | SRP, PL12 | NA | NA | NA |
REF8 [9] | 46/F | + | − | + | − | − | − | + | 3500 | SRP, PL12 | Mild | GC | Greatly improved |
REF9 [10] | 19/M | + | − | − | − | − | − | − | 311 | SRP, Mi2 | NAM | GC, AZA/MMF | Good response |